TEVA | Teva Pharmaceutical Industries Limited Stock Overview

(Stock Exchange: NYSE)

Day's Range	17.59 - 18.00
52 Week Range	8.06 - 19.08
Beta	0.88
Implied Volatility	53.89%
IV Rank	33.25%
Day's Volume	4,633,099
Average Volume	8,839,077
Shares Outstanding	1,132,990,000
Market Cap	20,257,861,200
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	1982-02-16

Valuation
Profitability
Growth
Health
P/E Ratio	-45.85
Forward P/E Ratio	3.86
EPS	-0.39
1YR Price Target	9.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	2017-11-27
Dividend PayDate	2017-12-12
Employees	35,001
Country	Israel
Website	TEVA

Teva Pharmaceutical Industries Ltd is based in Israel, together with its subsidiaries and associated companies the company is engaged in the development, manufacturing, marketing and distribution of generics, innovative medicines and biopharmaceuticals. The company operates business through three segments: North America, Europe and International Markets. Each business segment manages a product portfolio in its region, including generics, which include biosimilars and over-the-counter products, as well as innovative medicines.

TEVA's peers: BHC, ELAN, TAK, HLN, ZTS, VTRS, CTLT, MNK, SHPH, LFCR, LSDI, TLRY, CGC, ACB, SNDL, HEXO, CRON

*Chart delayed

Analyzing fundamentals for TEVA we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see TEVA Fundamentals page.

Watching at TEVA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on TEVA Technicals page.